479080-28-9

Basic information

• Product Name: 1-TERT-BUTYLOXYCARBONYL-3-(N-HYDROXYCARBAMIMIDOYL)PIPERIDINE
• Synonyms: 1-TERT-BUTYLOXYCARBONYL-3-(N-HYDROXYCARBAMIMIDOYL)PIPERIDINE;RAC-TERT-BUTYL 3-[(Z)-AMINO(HYDROXYIMINO)METHYL]PIPERIDINE-1-CARBOXYLATE;Tert-Butyl 3-(N-Hydroxycarbamimidoyl)piperidine-1-carboxylate;tert-Butyl 3-[amino(hydroxyimino)methyl]-1-piperidinecarboxylate;1-Boc-3-(N-HydroxycarbaMiMidoyl)piperidine
• CAS NO: 479080-28-9
• Molecular Formula: C₁₁H₂₁N₃O₃
• Molecular Weight: 243.31
• Mol File: 479080-28-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.23
• CAS DataBase Reference: 1-TERT-BUTYLOXYCARBONYL-3-(N-HYDROXYCARBAMIMIDOYL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-TERT-BUTYLOXYCARBONYL-3-(N-HYDROXYCARBAMIMIDOYL)PIPERIDINE(479080-28-9)
• EPA Substance Registry System: 1-TERT-BUTYLOXYCARBONYL-3-(N-HYDROXYCARBAMIMIDOYL)PIPERIDINE(479080-28-9)

Safety Data

• Hazardous Substances Data: 479080-28-9(Hazardous Substances Data)

Usage

General Description

1-TERT-BUTYLOXYCARBONYL-3-(N-HYDROXYCARBAMIMIDOYL)PIPERIDINE is a chemical compound that belongs to the class of piperidines. It is a derivative of piperidine and contains a tert-butyloxycarbonyl group as well as a N-hydroxycarbamimidoyl group. 1-TERT-BUTYLOXYCARBONYL-3-(N-HYDROXYCARBAMIMIDOYL)PIPERIDINE may have potential applications in the field of organic chemistry, pharmaceuticals, and materials science due to its diverse chemical properties and functional groups. The specific uses and applications of this compound would depend on further research and development in the respective fields.

InChI:InChI=1S/C11H21N3O3/c1-11(2,3)17-10(15)14-6-4-5-8(7-14)9(12)13-16/h8,16H,4-7H2,1-3H3,(H2,12,13)

Upstream product

• 91419-53-3 (+/-)-2-N-tert-butoxycabonylpiperidine-3-carbonitrile 
• 71381-75-4 N-(tert-butyloxycarbonyl)nipecotic acid 
• 91419-49-7 tert-butyl 3-carbamoylpiperidine-1-carboxylate 

Downstream Products

• 940868-22-4 tert-butyl 3-(4-{[(4-fluorobenzyl)amino]carbonyl}-5,6-dihydroxypyrimidin-2-yl)piperidine-1-carboxylate 

Relevant articles and documents

HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER

The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof Formula (I) and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of cancer. Further aspects of the present invention include combination therapies in which a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-cancer agent.

Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors

Human immunodeficiency virus type-1 (HIV-1) integrase, one of the three constitutive viral enzymes required for replication, is a rational target for chemotherapeutic intervention in the treatment of AIDS that has also recently been confirmed in the clinical setting. We report here on the design and synthesis of N-benzyl-5,6-dihydroxypyrimidine-4-carboxamides as a class of agents which exhibits potent inhibition of the HIV-integrase-catalyzed strand transfer process. In the current study, structural modifications on these molecules were made in order to examine effects on HIV-integrase inhibitory potencies. One of the most interesting compounds for this series is 2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 38, with a CIC95 of 78 nM in the cell-based assay in the presence of serum proteins. The compound has favorable pharmacokinetic properties in preclinical species (rats, dogs, and monkeys) and shows no liabilities in several counterscreening assays, highlighting its potential as a clinically useful antiviral agent.

CHEMICAL COMPOUNDS

This invention relates to biaryl ether derivatives of formula (I), wherein R1, R3, R4, X, W, Y and m are defined in the description, and to compositions containing them and the uses of such derivatives. The compounds of th